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ABSTRACT 
 
Objective: To evaluate the need and the magnitude of Levothyroxine (LT4) increase in 
hypothyroid pregnant women on liquid compared to tablet formulations. 
Methods: Patients were recruited by searching our „thyroid patients‟ database. The 
selection criteria were as follows: a) pregnant women on treatment for hypothyroidism 
(both liquid or tablet LT4) who have given birth at our hospital between February 2012 and 
January 2014; b) TSH and FT4 level obtained at least three months before missed 
menstrual cycle, with a TSH value less than 2.5 mIU/L; c) TSH and FT4 obtained within 12 
weeks of pregnancy, and each month subsequently.  
Results: During pregnancy, 8/31 (25.5%) of the women had to increase the dosage of 
LT4. Of these, 7/17 (41.2%) were on LT4 replacement therapy with tablet, and 1/14 (7.1%) 
with liquid formulation (p=0.038). Daily LT4 was significantly increased in liquid group only 
(52.9±19.5 vs 67.5±19.2 mcg/day (p=0.013). A logistic regression analysis showed that 
treatment with LT4 tablet was the only predictor of LT4 increase (OR 0.44, 95% CI 0.04-
0.83; p=0.031).  
Conclusion: Pregnant women on optimal replacement therapy before pregnancy, require 
increase of LT4 dose more often if on tablet than liquid formulation. 
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INTRODUCTION 
 
Hypothyroidism in pregnancy is defined as TSH above the trimester-specific reference 
range and is subdivided in subclinical or overt, depending on FT4 values within or below 
the normal range, respectively. Current Guidelines suggest to adopt local trimester specific 
range for TSH, and in absence of this, to consider an upper limit of 2.5mIU/L in the first, 
3.0 mIU/L in the second and 3.0-3.5 mIU\L in the third trimester [1-4]. The state of 
pregnancy requires an adaptation of thyroid function that results physiologically increased 
[5]. That is the reason why hypothyroid women on replacement treatment with 
Levothyroxine (LT4), usually require an increase of LT4 amount by 30-50% at the 
beginning of pregnancy [6]. The need and the magnitude of LT4 increase depend on the 
etiology of hypothyroidism and the pre-pregnancy TSH level [7, 8]. Traditionally, LT4 is 
administered in form of tablet, but soft gel capsule or liquid formulations are available in 
some European Countries. Recent studies have shown a better absorption of soft 
gel\liquid formulation than tablet, hesitating in more stable TSH values [9-11]. The aim of 
the study is to retrospectively evaluate the need and the magnitude of LT4 increase in 
hypothyroid pregnant women on liquid compared to tablet formulation. 
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SUBJECTS AND METHODS: 
 
Women were recruited by searching the database of patients treated and followed at the 
Thyroid Unit of the Department of Clinical and Experimental Science, University of Brescia. 
The search criteria were as follows: a) pregnant women on treatment for hypothyroidism 
(both liquid or tablet LT4) who have given birth at our hospital between February 2012 and 
January 2014; b) TSH and FT4 level obtained at least three months before missed 
menstrual cycle, with a TSH value less than 2.5 mIU\L; c) TSH and FT4 obtained within 12 
weeks of pregnancy, and each month subsequently; d) detailed LT4 treatment; e) detailed 
other drugs therapy (if any). As per protocol adopted in our Institution, in case of TSH 
higher than the pregnancy specific reference range, LT4 was increased by 25µg/day at 
each visit. All women satisfying the above criteria were enrolled in this study and informed 
consent was obtained from all subjects. The study was approved by the Institutional 
Review Board. Serum concentrations of free thyroxine (FT4 normal range 8.0-19 pg\ml, 
analytical sensitivity 1 pg\ml; intra and inter-assay coefficient of variation, 2.4 and 6.8%, 
respectively); TSH (normal range: 0.2-4.2 mIU\L, analytical sensitivity 0.004 mIU\L; intra 
and inter-assay coefficient of variation, 2.5 and 5.7%, respectively) were measured by 
means of chemiluminescence immunoassay using an automated analyser (Immulite 2000, 
DPC Cirrus, Los Angeles, CA, USA), employing commercial kits (Diagnostic Products 
Corporation, Los Angeles, CA, USA). Blood thyroid stimulating hormone (b-TSH) on 
neonatal Guthrie cards was measured by automated fluoro-immunoassay (Autodelfia 
technology; Perkin-Elfmer Life Science). The blood sample was collected between days 2-
4 after birth in the newborn and the b-TSH cur-off values was 10 mIU\L. 
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Statistics 
 
Statistical analysis was performed using SPSS 17.0 software (SPSS, Imnc, Evanston, IL, 
USA). Mann-Whitney U test was performed to evaluate TSH and FT4 distribution. 
Comparisons between groups and difference between proportions were calculated using 
ANOVA test for quantitative variables, as appropriate. A logistic analysis was performed to 
examine the influence of confounders on the hormonal thyroid profile. Two-tailed p<0.05 
was considered significant. Data are presented as mean ±standard deviation. 
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Results 
 
Between February 2012 and January 2014, 31 hypothyroid pregnant who satisfied the 
above mentioned criteria gave birth at our hospital. All the subjects were nulliparous, and 
suffered from Hashimoto's thyroiditis. Fourteen patients were in replacement therapy with 
liquid LT4 and 17 were on tablet. Baseline demographics and clinical characteristics are 
shown in Table I. No difference in age and body weight, were observed between patients 
on liquid and tablet treatment. All the patients assumed multivitamin pills containing iron 
and iodine. No difference was observed in thyroid function test before pregnancy between 
the tablet and the liquid group. Pre-pregnancy TSH and FT4 values were similarly 
distributed in the two groups. During pregnancy, 8/31 (25.5%) of the women had to 
increase the dosage of LT4. Of these, 3 women increased LT4 within 12 weeks, and 5 
between 13-24 weeks. Among them, 7/17 (41.2%) were on LT4 replacement therapy with 
tablet, and 1/14 (7.1%) with liquid formulation (p=0.038). The mean dose of LT4 from 
baseline to delivery was significantly increased only in women on tablet, as opposed to 
those on liquid therapy (52.9±19.5 vs 67.5±19.2 mcg/day (p=0.013), and 53.6±25.7 vs 
55.4±29.7 mcg/day (p=0.34), respectively. 
There was no significant difference between women who needed to increase LT4 and 
those who did not (Table II). There was no significant difference in parameters of newborn 
from mothers who needed to increase LT4 and those who did not (Table III).   
A logistic regression analysis taking into account age, pre-pregnancy and delivery weight, 
gestational weight gain, TSH values, showed that treatment with LT4 tablet was the only 
predictor of LT4 increase (OR 0.44, 95% CI 0.04-0.83; p=0.031).  
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Discussion 
 
Either American or European Guidelines about treatment of thyroid disease in pregnancy 
suggest to treat hypothyroid women in order to keep TSH within trimester specific 
reference range [1-4]. Increased TSH levels are associated with adverse events like 
miscarriage, gestational hypertension and preeclampsia, gestational diabetes, intrauterine 
growth restriction, neonatal low birth weight, reduced intelligence quotient in the offspring 
[12, 13]. Given the well known variation in demand of thyroid hormones during pregnancy, 
a prospective study demonstrated that in hypothyroid women, an increase of two tablet per 
week is able to maintain TSH within the pregnancy reference range, then mimicking the 
physiological adaptation of an healthy thyroid to the pregnant state [14]; the need for an 
increase of LT4 dosage may be even higher than 30% in hypothyroidism induced by 
radioiodine or total thyroidectomy; other than the etiology of hypothyroidism, also the pre-
pregnancy TSH level should be taken into account when deciding the variation dose: data 
suggest that increased LT4 dosage is necessary in 50% of cases when pre pregnancy 
TSH is 1.2-2.4 mIU\L versus 17% when TSH is lower than 1.2 mIU\L [7, 15, 16]. 
In the present study that evaluated LT4 treatment in hypothyroid patients on liquid or tablet 
formulation we observed that, despite similar pre-pregnancy TSH levels (mean and 
distribution) the liquid-treated group require to increase the LT4 dose in a minority of 
cases. A possible explanation for this result may rely on the different characteristic of 
absorption demonstrated by the two formulations. Indeed, the gastric pH is one of the most 
important factors that influence the absorption of LT4, in an inversely proportional manner: 
the absorption capacity decreases with the increase of pH [17, 18]. Centanni et al. have 
demonstrated that patients with impaired acid secretion require an increase dose of 
thyroxine, confirming that normal acid gastric secretion is necessary for effective 
absorption of oral LT4 [19]. It is well known that during pregnancy gastric emptying and 
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small intestine motility are reduced by 30-50% due to elevation of progesterone (20-22). In 
addition, these changes alter bioavailability parameters like maximum concentration 
(Cmax) and time to maximum concentration (Tmax) of orally administered medication. The 
decrease in Cmax and increase in Tmax particularly affect medication taken daily as a 
single dose [23]. Another relevant modification during pregnancy is represented by an 
increase in gastric pH, due to a reduction of H+ secretion and an increase in mucus 
production, which may increase the ionization of weak acids, tending to reduce their 
absorption more than that of weak bases [20, 21]. Many recent reports have clearly 
demonstrated that liquid LT4 formulation circumvents these problems, in patients taking 
proton pump inhibitors, those suffering from gastric related T4 malabsorption, those 
assuming T4 with coffee or fed by enteral tube, and also those submitted to bariatric 
surgery [24-28]. As our pregnant patients on tablet required to increase LT4 more often 
than those on liquid, it is possible that the usual increase in exogenous LT4 requirement 
may be partly due to altered LT4 tablet absorption and not exclusively to pregnancy-
related thyroid hormone increased demand. A major concern is represented by the alcohol 
content (243mg) that is present in vials of liquid formulation. As a matter of fact, current 
guidelines recommend abstinence from alcohol for women planning pregnancy, at 
conception, and during pregnancy [29, 30]. A recent meta-analysis did not find a 
significant increase in risk of low birth weight and small for gestational age for alcohol daily 
intake lower than 10 g, and risk of preterm birth for a daily intake lower than 18 g [31]. Our 
study as well did not find any difference between in characteristics of newborn from mother 
on liquid and tablet formulation.  
In conclusion, although limited by the retrospective collection of data, and the small 
number of patients, results show that hypothyroid pregnant women on optimal 
replacement therapy before pregnancy, require increase of LT4 dose more often if on 
tablet than liquid formulation. Randomized prospective studies are necessary to confirm 
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this preliminary finding, that may have relevant clinical implications in the treatment of 
hypothyroidsm in pregnancy. 
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Table I. Baseline demographics and clinical characteristics of women before pregnancy 
 
 Hypothyroid women on 
liquid LT4 (14 patients) 
Hypothyroid women on 
tablet LT4 (17 patients) 
p value 
Age (yrs) 28±3.8 27.3±3.5 0.599 
Weight (kg) 59.5±2.8 58.8±4.2 0.609 
LT4 dosage (mcg) 53.6±25.7 52.9±19.5 0.939 
TSH (mUI/L) 1.6±0.8 1.4±0.8 0.592 
fT4 (pg/mL) 10.9±1.4 10.3±1.3 0.308 
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Table II. Age and body weight of women who needed to increase LT4 and those who did 
not. 
 
 Women who needed to 
increase LT4 dosage (8 
patients) 
Women with no need to 
increase LT4 dosage (23 
patients) 
p 
value 
Age (yrs) 26.1±3.1 28.1±3.7 0.183 
Weight pre-pregnancy (kg) 57.8±3.9 59.6±3.4 0.212 
Weight at delivery (kg) 69.9±4.2 71.1±3.7 0.433 
Increase of weight during 
pregnancy (%) 
21.1±2.2 19.4±2.5 0.102 
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Table III. Clinical parameters of newborn from mothers who needed to increase LT4 and 
those who did not. 
 Newborn from mother who 
has increased the LT4 
dosage (8 neonates) 
Newborn from mother who 
has not increased the LT4 
dosage (23 neonates) 
p 
value 
Male/Female 2/6 8/15 0.483 
Gestational age (weeks) 40.1±0.8 39.3±0.9 0.055 
Head circumference (cm) 35.2±1.1 35.4±1.8 0.771 
Weight (g) 3631±0.36 3.683±0.29 0.687 
Length (cm) 50.6±3.3 51.1±2.8 0.681 
Apgar score 1st minute  8.4±1.3 8.3±1.2 0.844 
b-TSH (mU/L) 6.8±2.1 6.8±1.3 0.969 
 
 
